Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
Donald Notman, Chief Financial Officer and Chief Operating Officer of Ocular Therapeutix, Inc. (OCUL), reported a routine, non-discretionary sale of company stock tied to tax withholding after restricted stock unit vesting. The Form 4 shows 1,066 shares of common stock were sold on 09/02/2025 at a weighted-average price of $12.43 under a durable automatic sales instruction to satisfy withholding from RSUs that vested on 08/29/2025. After the reported sale, the reporting person beneficially owned 308,807 shares, which includes 1,429 shares purchased under the company’s ESPP on 06/30/2025. The filing is an individual Form 4 reporting officer activity and clarifies the sale was not a discretionary trade.
Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 1,066 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $13,245.37. The filing shows these shares represent part of the issuer's outstanding common shares of 173,995,221 and identifies the approximate sale date as 09/02/2025 on NASDAQ. The shares were acquired on 08/29/2025 as restricted stock vesting under a registered plan; payment and transfer were recorded that same date. The filer reports no securities sold in the past three months and includes the standard representation regarding absence of undisclosed material adverse information.
Ocular Therapeutix insider Peter Kaiser, the company's Chief Development Officer, reported the sale of 3,011 shares of common stock on 08/25/2025 under a pre-established automatic sale instruction to cover taxes from RSU vesting. The weighted-average sale price was $12.04 per share, with individual trade prices ranging from $11.89 to $12.1548. After the transactions, the reporting person beneficially owned 204,093 shares. The filing notes the sales were non-discretionary and executed to satisfy tax withholding.
Ocular Therapeutix insider sale summary: Chief Strategy Officer Sanjay Nayak executed automatic sales of 1,885 shares of Ocular Therapeutix common stock on 08/25/2025 to satisfy tax withholding for restricted stock units that vested on 08/22/2025. The sales were made under a pre-established durable automatic sale instruction and were not discretionary. The weighted-average price reported for the sales is $12.04, with individual trade prices ranging from $11.89 to $12.1521. Following the reported disposals, the reporting person beneficially owned 279,738 shares.
Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc. (OCUL), sold 3,063 shares of the company's common stock on 08/25/2025 at a weighted average price of $12.04 per share. The sale was executed under a durable automatic sale instruction adopted April 9, 2024, as a sell-to-cover to satisfy tax withholding tied to restricted stock units that vested on 08/22/2025. Following the reported transactions, Heier beneficially owned 259,911 shares. The filing notes the sales were not discretionary and were executed across prices ranging from $11.89 to $12.16.
Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc. (OCUL), reported the sale of 21,494 shares of the company's common stock on 08/25/2025 under a pre-established durable automatic sale instruction intended to satisfy tax withholding for restricted stock units that vested on 08/22/2025. The shares were sold at a weighted average price of $12.04, with transaction prices ranging from $11.89 to $12.18. After the sale, the reporting person beneficially owned 3,227,244 shares directly and 250,361 shares indirectly through the Pravin Dugel 2024 Irrevocable Trust. The filing was signed by an attorney-in-fact on behalf of Mr. Dugel on 08/27/2025.
Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 21,494 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $258,757.67. The filing shows 173,995,221 shares outstanding and an approximate sale date of 08/25/2025. The shares were acquired on 08/22/2025 by restricted stock vesting under a registered plan and payment/transfer is recorded as 08/22/2025.
The filer certifies no undisclosed material adverse information. No other sales in the past three months are reported. This is a routine notice of proposed sale under Rule 144 showing a short waiting period between vesting and the planned sale.
Ocular Therapeutix (OCUL) filed a Form 144 reporting an intended sale of 1,885 common shares through Morgan Stanley Smith Barney LLC on 08/25/2025 on NASDAQ with an aggregate market value of $22,701.62. The shares were acquired on 08/22/2025 as restricted stock vesting under a registered plan and were received as compensation. The filer reports no securities sold by the same person in the past three months and affirms no undisclosed material adverse information.
Ocular Therapeutix filed a Form 144 notifying of a proposed sale of 3,063 shares of its common stock that were acquired through restricted stock vesting on 08/22/2025. The filing lists the intended sale date as 08/25/2025, an aggregate market value of $36,882.81, and indicates the shares trade on NASDAQ. The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
The filer represents no material nonpublic information is known and notes no sales by the person in the past three months. Certain identifying fields (for example, filer CIK and filer name) are not populated in the provided content.
Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 3,011 shares of common stock with an aggregate market value of $36,252.74. The shares represent a very small portion of the company’s reported 173,995,221 outstanding shares and are listed for sale on NASDAQ with an approximate sale date of 08/25/2025.
The filing notes the shares were acquired on 08/22/2025 from restricted stock vesting under a registered plan and that no securities of the issuer were sold by the reporting person in the past three months. The filer certifies there is no undisclosed material adverse information about the issuer in connection with this notice.